Shanghai Junshi Biosciences Co., Ltd. (SHA:688180)

Market Cap	40.26B +53.6%
Revenue (ttm)	2.50B +28.2%
Net Income	-875.17M
EPS	-0.87
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,977,192
Average Volume	21,302,791
Open	44.35
Previous Close	44.38
Day's Range	43.99 - 45.48
52-Week Range	28.24 - 51.40
Beta	0.55
RSI	78.14
Earnings Date	Apr 27, 2026

About SHA:688180

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company’s product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2,903
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688180

Financial Performance

In 2025, SHA:688180's revenue was 2.50 billion, an increase of 28.23% compared to the previous year's 1.95 billion. Losses were -875.17 million, -31.68% less than in 2024.